EASL CONGRESS

Consensus Conference

6 May 2025, 9:30 - 17:30 CEST

Trial design and end-points in HCC

EUR 102.85

Organised by EASL, AASLD, ASCO and ILCA

Join us for a high-impact, one-day event dedicated to redefining clinical trial design and end-points in HCC.
Building on recent breakthroughs, we will focus on what truly defines clinical benefit, set new standards for upcoming Phase III trials, and explore innovative regulatory strategies.

Steering Committee

Josep M. Llovet
Chair

Richard Finn
Co-chair

Tim Meyer
Co-chair

Arndt Vogel
Co-chair

Amit Singal
Co-chair

Register now:

EASL CONGRESS

Consensus Conference

6 May 2025, 9:30 - 17:30 CEST

Trial design and end-points in HCC

Explore an unmatched programme!

- Session 1: A thorough review of regulatory oncology end-points including OS, PFS, TTP, ORR, and PROs.
- Session 2: Key discussions on early and intermediate HCC trial designs, end-point selections, and regulatory considerations.
- Session 3: Advanced HCC trial strategies emphasising survival outcomes, patient stratification, and clinical relevance.
- Session 4: Emerging topics such as biomarker use, patient quality-of-life assessment, and strategies to address disparities and patient engagement in clinical trials.

Discover multi-perspective approaches from academia, regulatory bodies, and patient representatives.

Outcomes from the event will form the basis of a published consensus manuscript.

Organised by: EASL™ The Home of Hepatology

With support from: AASLD American Association for the Study of Liver Diseases, ASCO, ILCA International Liver Cancer Association